Spots Global Cancer Trial Database for homologous recombination deficiency (hrd)
Every month we try and update this database with for homologous recombination deficiency (hrd) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | NCT01063517 | Gastric Cancer | olaparib paclitaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | NCT00753545 | Ovarian Cancer | AZD2281 matching placeb... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | NCT04666740 | Metastatic Panc... Homologous Reco... | Pembrolizumab Olaparib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | NCT02810743 | Breast Cancer | ddAC-CP-Olapari... ddAC-mini CTC | 18 Years - 65 Years | The Netherlands Cancer Institute | |
| Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | NCT06120972 | Ovarian Cancer | Olaparib tablet | 18 Years - | University of Pittsburgh | |
| Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | NCT06120972 | Ovarian Cancer | Olaparib tablet | 18 Years - | University of Pittsburgh | |
| Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | NCT02810743 | Breast Cancer | ddAC-CP-Olapari... ddAC-mini CTC | 18 Years - 65 Years | The Netherlands Cancer Institute | |
| Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | NCT03712930 | Metastatic Cast... Homologous Reco... | Pamiparib | 18 Years - | BeiGene | |
| Phase I Comparative Bioavailability Study | NCT00777582 | Solid Tumors | AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | NCT02655016 | Ovarian Neoplas... | Niraparib Placebo | 18 Years - | Tesaro, Inc. | |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | NCT04666740 | Metastatic Panc... Homologous Reco... | Pembrolizumab Olaparib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | NCT04666740 | Metastatic Panc... Homologous Reco... | Pembrolizumab Olaparib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | NCT03712930 | Metastatic Cast... Homologous Reco... | Pamiparib | 18 Years - | BeiGene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
